← k3vl4r
Log inGet started →

TAK (Takeda Pharmaceutical Co ADR) Price Forecast

AI-generated price forecast for Takeda Pharmaceutical Co ADR (TAK) across 1-hour, 4-hour, daily and weekly horizons — updated continuously, with a public accuracy track record.

The desk streams live daily· see the schedule →

As of September 2026: K3vl4r's AI model currently reads TAK as 2/2 bearish · strong across its horizons (0 of 2 timeframes pointing up), with a last price of 18.71. See our public, auditable track record →

📈 Daily Top Picks beating the S&P 500 since launch→✓ Public, verifiable track record Live system status💎 Get the full AI report · pay with XRP

Last price

18.71

AI outlook

2/2 bearish · STRONG

Timeframes up

0 / 2

Share𝕏PostTelegram

TAK forecast by horizon

HorizonDirectionProjected move (end of horizon)Bullish prob.
1-hour———
4-hour~4 weeks out———
Daily~4 months out▼ Down-17.16%0%
Weekly~1.8 years out▼ Down-31.68%—

Latest TAK news

From the market-news feed the forecasts are read against.

  • Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? · Zacks · Sep 2
  • Takeda and Weave Bio collaborate on AI-driven automation in drug development · Pharmaceutical Technology · Sep 2
  • The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones · Simply Wall St. · Sep 1
  • Why Is Protagonist Therapeutics (PTGX) In Focus After MIMRYLO FDA Approval? · Simply Wall St. · Sep 1
  • Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug · Benzinga · Aug 31

🔒

See the full TAK forecast

Interactive forecast chart, price targets, and Monte-Carlo confidence bands — plus the daily AI Top Picks book. Free to start, no card required.

Create a free account →

Already have one? Log in

TAK forecast — frequently asked

Will TAK go up?

K3vl4r's AI model currently reads TAK as 2/2 bearish · STRONG — 0 of 2 forecast horizons point up, so the overall read is leaning to the downside. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

What is the TAK price prediction for 2026?

K3vl4r's model projects TAK toward $18.68 over the next ~4 months, a -0.2% move from $18.71. Projections update continuously as new data arrives and are inherently uncertain. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

What price could TAK reach?

Over its longest horizon (~~1.8 years), the model's projected target for TAK is $18.64 (-0.3% vs $18.69). Confidence decreases the further out the horizon, so treat longer-range targets as one scenario, not a guarantee. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

Part of Healthcare forecasts — browse the full sector.

More AI forecasts

STIMGHZNTLVSTMACHCLDXTVRDITGRARDXHCSGMISTCMPXIMMXKTTA

Will TAK reach…?

Will TAK reach $25.00?Will TAK reach $50.00?Will TAK reach $100.00?

Or see the full TAK price prediction (2027–2040), or the forecast for today, tomorrow and this week.

Compare TAK

TAK vs STIMTAK vs GHTAK vs ZNTLTAK vs VSTMTAK vs ACHTAK vs CLDX

Curious how this is generated? Read how K3vl4r forecasts — the model, the confidence bands, and what we deliberately do not claim.

K3vl4r publishes a public, auditable track record of its Daily Top Picks — see the live results.

Forecasts are model-generated estimates for informational purposes only and are not financial advice. Markets are risky; past accuracy does not guarantee future results. See our Risk Disclosure.

StreamWatch on Kick·Watch on YouTube
k3vl4rTop PicksTrack recordChart indicatorsToday's outlookStream scheduleBiggest moversMarket heatmapForecasts by sectorAI reportsMarket videosCompareMethodologyBest AI toolsAboutFAQ◈ KVLHow KVL worksTokenomicsPricingX (Twitter)YouTube — daily showsTikTokTwitch — live forecastingDiscord community

Join the community on Discord and catch the desk stream live on Kick or YouTube. Create a free account →

Forecasts are AI-generated; written analysis is AI-assisted and human-reviewed. Informational only, not financial advice. See Terms, Risk Disclosure, Privacy · Methodology · Status.